MAPK7

Across TCGA pan-cancer cohorts, MAPK7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAPK7 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher MAPK7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPK7 expression acts as an unfavorable survival marker.

KICH, LIHC, and HNSC are the cancer types where MAPK7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.162	0.862	.014	10	view →
LIHC	DFS	Median	All	0.239	0.558	.030	3	view →
HNSC	OS	Median	II,III,IV	0.178	0.672	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAPK7–KICH (DFS)

Open the KICH breakdown →